As health-tech startups and pharmaceutical innovators drive rapid adoption of injectable weight-loss drugs, new UK research has raised questions about their durability as long-term obesity solutions. While medications such as semaglutide (Wegovy...
Biocon Pharma, a subsidiary of Biocon Ltd, has received approval from the United States Food and Drug Administration (US FDA) for its generic everolimus tablets for oral suspension. The approval was granted under an Abbreviated New Drug Applicatio...
Eli Lilly and Company announced today a major partnership with NVIDIA to launch a first-of-its-kind AI co-innovation lab designed to take on some of the pharmaceutical industry’s hardest problems. The collaboration will see the two companies...
AbbVie and RemeGen have entered into an exclusive global licensing agreement to develop and commercialise RC148, an investigational bispecific antibody for cancer treatment. Under the agreement, AbbVie will hold rights to RC148 outside Greater Ch...
.jpeg)
Aragen launches CHOMax, a cell line and early manufacturing platform, taking monoclonal antibody programmes from DNA to IND-enabling clinical supply in 10 months.
.png)
Lupin Limited has signed an exclusive license, supply, and distribution agreement to commercialize Bofanglutide in India, marking a major step in the battle against type 2 diabetes and obesity. Under the pact with China’s Gan&Lee Pharmaceuticals...
Merck & Co. has initiated KANDLELIT-007, a global Phase 3 clinical trial evaluating its investigational oral KRAS G12C inhibitor calderasib (MK-1084) in combination with KEYTRUDA QLEX™, a subcutaneous formulation of pembrolizumab with berahyalur...
Eli Lilly’s Zepbound-Taltz combination has delivered strong results in a late-stage clinical trial, showing improved arthritis relief alongside meaningful weight loss, reinforcing the growing link between obesity management and inflammatory dis...
Shilpa Medicare Limited is preparing to seek US approval for its Ondansetron Extended-Release Injection (OERIS) within the next two years and is actively exploring licensing partners. The decision follows a successful Phase 3 trial in India, with..
Granules India announced today that U.S. based company, Granules Pharmaceuticals, Inc., has gotten probable designation of the U.S. Food and Drug Administration (FDA) on its generic amphetamine prolonged discharge pills that treat attention...
.jpg)
.jpg)
, CDSCO.jpg)